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Learning	  Objec8ves	  
1.  Par8cipants	  will	  learn	  about	  the	  current	  state	  
of	  gene8cs,	  including	  genome	  wide	  
associa8on	  studies	  (GWAS),	  Copy	  Number	  
Variants	  (CNVs)	  and	  next	  genera8on	  
sequencing.	  
2.  Some	  Case	  Illustra8ons	  will	  be	  presented.	  	  
3.  A	  review	  of	  current	  progress	  in	  psychiatric	  
	  gene8cs	  will	  be	  presented.	  
Learning	  Objec8ve	  #1	  –	  Current	  
methods:	  Associa8on	  tes8ng	  
•  Is	  a	  muta8on	  associated	  more	  with	  people	  with	  a	  
disease	  vs.	  people	  without	  the	  disease?	  
•  This	  is	  Case-­‐Control	  associa8on.	  
•  If	  tes8ng	  only	  one	  marker	  or	  muta8on	  (or	  SNP	  or	  
CNV),	  then	  p	  value	  of	  0.05	  is	  accepted	  for	  
rejec8on	  of	  null	  hypothesis	  with	  Fisher’s	  exact	  t-­‐
test.	  
•  If	  one	  tests,	  for	  example,	  610,000	  muta8ons	  or	  
markers,	  then	  the	  signiﬁcance	  level	  must	  be	  
adjusted	  for	  mul8ple	  tes8ng,	  so	  0.05	  divided	  by	  
610,000	  =	  8e-­‐8.	  
Single Nucleotide Polymorphism (SNP) 
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• 	  Every	  100-­‐200	  base	  pairs	  
• 	  ~20,500,000	  SNPs	  
currently	  known	  	  	  
• 	  At	  least	  1%	  of	  popula8on	  
• 	  Labeled	  with	  an	  rs	  #	  
• 	  (i.e.	  rs1234)	  
Measuring	  SNPs	  
What	  are	  SNPs	  good	  for?	  
•  Everything?	  
•  i.e.	  Earwax	  type	  	  
Genotype	   Eﬀect	  
rs17822931(C;C)	   Wet	  earwax	  
rs17822931(C;T)	  
	  
Wet	  earwax	  
Rs17822931(T;T)	   Dry	  earwax	  
An	  Example	  with	  ApoE4	  
Genotype	   Eﬀect	  
rs429358(C;C)*	   >10x	  increased	  risk	  for	  Alzheimer's	  	  
	  1.4x	  increased	  risk	  for	  heart	  disease	  
rs429358(C;T)	   >3x	  increased	  risk	  for	  Alzheimer’s	  
	  1.4x	  increased	  risk	  for	  heart	  disease	  
rs429358(T;T)	   Common	  
*~15%	  of	  the	  popula8on	  carries	  a	  C	  
Alzheimer’s	  –	  ApoE4	  	  
Wafarin	  Sensi0vity	  
•  Polymorphisms	  in	  2C9,	  VKORC1	  &	  4F2	  to	  
op8mize	  dosage	  
–  rs2108622	  accounts	  for	  15%	  of	  dosage	  varia8on	  
Published Genome-Wide Associations through 3/2009,                 
398 published GWA at p < 5 x 10-8  NHGRI GWA Catalog 
www.genome.gov/GWAStudies 
Published	  Genome-­‐Wide	  Associa0ons	  through	  06/2011,	  
1,449	  published	  GWA	  at	  p≤5x10-­‐8	  for	  237	  traits	  
NHGRI	  GWA	  Catalog	  
www.genome.gov/GWAStudies	  

Copy Number Variants (CNVs) or 
INDELS (insertions or deletions) 
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Patchwork	  People,	  Nature	  2005	  
Some	  facts	  about	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
•  Inser8ons	  &	  Dele8ons	  (1000	  base	  pairs	  or	  more)	  
•  >1%	  of	  our	  genomes	  diﬀer	  in	  copy	  number	  
–  Compared	  to	  ~0.1%	  for	  SNPs	  
•  New	  muta8on	  rate	  3-­‐4x	  higher	  than	  SNPs	  
–  But	  only	  1%	  of	  CNVs	  are	  new	  muta8ons	  (most	  are	  inherited)	  
•  Can	  inﬂuence	  gene	  expression	  even	  1	  megabase	  away	  
•  Types	  of	  CNVs	  
–  ~40%	  are	  dele8ons	  
–  ~40%	  duplica8ons	  
–  ~20%	  other	  (i.e.	  both,	  complex,	  mul8-­‐allelic)	  	  
Measuring	  CNVs	  
Karyotype	  
Fiber	  FISH	  
Microarray	  	  
CGH	  Array	  
qPCR	  
Q:	  Do	  I	  have	  any	  CNVs?	  
A:	  Yes.	  Lots.	  
Q:	  How	  many?	  
A:	  It	  varies	  per	  person	  but	  in	  
the	  range	  of	  Hundreds.	  
CNV	  Detec0on:	  An	  Imperfect	  Science	  
Pla[orm	   So\ware	   CNVs	   Unique	   Median	  Size	  (kb)	  
Aﬀy	  6.0	   Partek	   12	   0	   38	  
Aﬀy	  GTC	   29	   9	   46	  
iParern	   77	   24	   9	  
Birdsuite	   126	   75	   10	  
Illumina	  1M	   quan8SNP	   36	   9	   38	  
iParern	   53	   28	   28	  
PennCNV	   63	   41	   23	  
Nimblegen	  42M	   GADA	   1095	   974	   3	  
Venter	  DNA	  
            & Disease 
•  Au8sm	  
–  dup	  15q11-­‐13	  (maternal)	  (1994)	  
•  Schizophrenia	  
–  del	  22q11	  (VCFS)	  (1999)	  
•  Parkinsons	  
–  dup	  SNCA	  (2003)	  
•  HIV/AIDS	  risk	  
–  dup	  CCL3L1	  (2003)	  
•  Autoimmunity	  
–  del	  FCGR3B	  	  &	  SLE	  (2006)	  
•  Crohn’s	  disease	  
–  ≤	  3	  copies	  of	  HBD-­‐2	  =	  higher	  risk	  
(2006)	  
	  
•  Age-­‐related	  macular	  
degenera8on	  (2006)	  
–  del	  CFHR1	  and	  CFHR3	  =	  lower	  risk	  
•  Alzheimer’s	  disease	  
–  dup	  APP	  (2006)	  
•  Pancrea88s	  
–  dup	  PRSS1	  (2006)	  
•  Prostate	  cancer	  
–  del	  UGT2B17	  ?	  (2006)	  
•  ITP	  
–  varia8on	  in	  FCGR2	  and	  FCGR3	  
(2008)	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Clinical	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  2011	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Chromosomal	  microarray	  tes0ng	  inﬂuences	  medical	  management.	  
Coulter	  ME,	  Miller	  DT,	  Harris	  DJ,	  Hawley	  P,	  Picker	  J,	  Roberts	  AE,	  Sobeih	  MM,	  Irons	  M.	  
	  
PURPOSE:	  	  
Chromosomal	  microarray	  (CMA)	  tes8ng	  provides	  the	  highest	  diagnos8c	  yield	  for	  clinical	  tes8ng	  of	  
pa8ents	  with	  developmental	  delay	  (DD),	  intellectual	  disability	  (ID),	  mul8ple	  congenital	  anomalies	  
(MCA),	  and	  au8sm	  spectrum	  disorders	  (ASD).	  Despite	  improved	  diagnos8c	  yield	  and	  studies	  to	  support	  
cost-­‐eﬀec8veness,	  concerns	  regarding	  the	  cost	  and	  reimbursement	  for	  CMA	  have	  been	  raised	  because	  
it	  is	  perceived	  that	  CMA	  results	  do	  not	  inﬂuence	  medical	  management.	  
METHODS:	  	  
We	  conducted	  a	  retrospec8ve	  chart	  review	  of	  CMA	  tes8ng	  performed	  during	  a	  12-­‐month	  period	  on	  
pa8ents	  with	  DD/ID,	  ASD,	  and	  congenital	  anomalies	  to	  determine	  the	  propor8on	  of	  cases	  where	  
abnormal	  CMA	  results	  impacted	  recommenda8ons	  for	  clinical	  ac8on.	  
RESULTS:	  	  
Among	  1792	  pa8ents,	  13.1%	  had	  clinically	  relevant	  results,	  either	  abnormal	  (n	  =	  131;	  7.3%)	  or	  variants	  
of	  possible	  signiﬁcance	  (VPS;	  n	  =	  104;	  5.8%).	  Abnormal	  variants	  generated	  a	  higher	  rate	  of	  
recommenda8on	  for	  clinical	  ac8on	  (54%)	  compared	  with	  VPS	  (34%;	  Fisher	  exact	  test,	  P	  =	  0.01).	  CMA	  
results	  inﬂuenced	  medical	  care	  by	  precipita8ng	  medical	  referrals,	  diagnos8c	  imaging,	  or	  speciﬁc	  
laboratory	  tes8ng.	  
CONCLUSIONS:	  	  
For	  all	  test	  indica8ons,	  CMA	  results	  inﬂuenced	  medical	  management	  in	  a	  majority	  of	  pa8ents	  with	  
abnormal	  variants	  and	  a	  substan8al	  propor8on	  of	  those	  with	  VPS.	  These	  results	  support	  the	  use	  of	  
CMA	  as	  a	  clinical	  diagnos8c	  test	  that	  inﬂuences	  medical	  management	  for	  this	  pa8ent	  popula8on.	  
Learning	  Objec8ve	  #1:	  Massively	  Parallel	  
and	  Next	  Genera8on	  Sequencing	  
Exome	  Sequencing	  is	  a	  	  
Revolu0onary	  Technology!	  
Learning	  Objec8ve	  #2:	  
Some	  Case	  Illustra8ons	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Down	  Syndrome	  
Down	  Syndrome	  
Christopher	  Joseph	  "Chris"	  Burke	  (born	  August	  
26,	  1965)	  is	  an	  American	  actor	  and	  folk	  singer,	  
who	  lives	  with	  Down	  syndrome,	  who	  has	  
become	  best	  known	  for	  his	  character	  Charles	  
"Corky"	  Thacher	  on	  the	  television	  series	  Life	  
Goes	  On.	  
	  
And	  there	  are	  people	  with	  Mosaic	  Down	  
Syndrome,	  who	  are	  much	  less	  aﬀected.	  
Velocardiofacial	  (22q11.2)	  Syndrome	  
16p11.2 deletion 
Fernandez B A et al. J Med Genet 2010;47:195-203 
©2010 by BMJ Publishing Group Ltd 
Clinical photographs. (a and b) Proband 2 (de novo deletion 16p11.2). Note long 
narrow palpebral fissures, short delicate nose, short neck and brachydactyly with 
2–3 cutaneous toe syndactyly. (c and d) Mother of proband 3 (both with 
deletions). Note her large ears, smooth philtrum and short fifth toes. 	  
16p11.2 duplication 
Fernandez B A et al. J Med Genet 2010;47:195-203 
©2010 by BMJ Publishing Group Ltd 
Clinical photographs. (e) Proband 5 who has a maternally inherited 
duplication. (f) Proband 5 (note smooth philtrum) and her healthy duplication 
positive sister. (g) Duplication positive mother of proband 5, who also has a 
smooth philtrum. (h) Proband 6 (inherited duplication and oliogohydramnios 
sequence). Note her frontal bossing, receding hairline, hypoplastic 
supraorbital ridges and smooth philtrum. (i) Proband 6's right hand showing 
fifth finger clinodactyly. 	  
16p11.2	  dele8on,	  not	  in	  mother	  or	  
father,	  only	  in	  child.	  	  
5	  years	  old,	  but	  developmental	  
age	  of	  2	  year	  old.	  
Speaks	  a	  few	  words,	  almost	  
unintelligible.	  
Very	  hyperac8ve.	  
Can	  be	  withdrawn	  and	  has	  at	  
8mes	  been	  diagnosed	  with	  
“au8sm”.	  
*Private	  Photograph	  –	  Do	  not	  further	  distribute.	  

Laurence-­‐Moon	  Syndrome,	  now	  known	  as	  Bardet-­‐Biedl	  Syndrome	  
Published	  in	  “John	  Langdon	  Down:	  A	  Caring	  Pioneer”,	  by	  O	  Conor	  Ward,	  1998.	  
Master	  Crazsman	  
Most	  famously	  designed	  The	  Great	  
Eastern,	  a	  10	  foot	  long	  model	  ship	  
with	  incredible	  detail.	  
	  
Deaf	  and	  nearly	  mute	  –	  Nonverbal,	  
Obsessed	  with	  one	  topic	  of	  
building	  things.	  
Thought	  to	  be	  mentally	  retarded.	  
Usually	  quiet	  and	  reserved,	  but	  
some8mes	  was	  intolerant	  of	  
advice,	  suspicious	  of	  strangers,	  and	  
ill-­‐tempered	  and	  violent.	  
“The	  clinical	  and	  pathological	  
evidence	  of	  a	  pervasive	  
developmental	  disorder	  points	  to	  a	  
retrospec8ve	  diagnosis	  of	  au8sm.”	  
Historical 
The Victorian genius of Earlswood - a 
review of the case of James Henry Pullen 
Caoimhghin S Breathnach, Conor Ward 
Summary 
London born James Henry Pullen (1836-1915) was 
admitted to Essex Hall in Colchester, an institution catering 
for learning disability, at the age of 13. Here his artistic 
talent was spotted before he moved two years later to 
Earlswood Asylum for Idiots, where he was apprenticed to 
woodworking. Such was his manual skill he was eventually 
employed making furniture for the asylum. His artistic 
propensity was similarly encouraged and although he never 
mastered coherent speech he has left a pictorial 
autobiography of some distinction. At observation he 
underwent detailed examination by Frederich Sano (1871-
1946), particular attention being paid to tokens of arrested 
development. The clinical and pathological evidence of a 
pervasive developmental disorder points to a retrospective 
diagnosis of autism. 
Key words: History; Autism; Victorian genius; Learning 
disability; Developmental disorder. 
Introduction 
In 1870 Sequin described children who had 'a useless 
protrusion of a single faculty accompanied by a woeful 
general impotence'.' Langdon Down introduced the term 
idiots savants to describe them.' The first idiot savant recog-
nised in England was Jedediah Buxton, an illiterate 
Derbyshire farmhand who could multiply two 39 digit 
numbers.3 Of the seven cases described by Langdon Down, 
the best known was James Henry Pullen, known colloquially 
as the Genius of Earlswood. Langdon Down's identification 
of the syndrome had previously been referred to in 1865.' 
Clinical history 
Pullen's parents were first cousins. They lived in Peckham 
in south London. Of 13 children six died in infancy and only 
three survived into adult life.' His brother William too, also 
cared for in an institution, had exceptional artistic skills. James 
Henry combined primitive speech with sign language. He 
could not write in coherent sentences, but he drew over 80 
sketches illustrating his life. These present a unique life story. 
Boats fascinated him from an early age. Wearing skirts, and 
not yet in breeches, he is seen at the age of nine years 
making a crude model ship from a wooden box. (Figure 1, left 
*Caoimhghin 5 Breathnach, MD, PhD, 
Con or Ward, MD, PhD, FRCPl, Departments of Anatomy & 
Physiology, Paediatrics and Maurice Kennedy Research Centre 
for Emeritus Staff, NUl University College Dublin, Ireland. 
*Correspondence 
SUBMlTIED: MARCH 11, 2005. ACCEPTED: OCTOBER 20. 2005. 
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pane1. Boys usually graduated to wearing breeches at the 
age of six years. Assuming that he inscribed the correct date 
his being still unbreeched at this late age suggests that he 
was seen in the family to have failed to reach an appropriate 
developmental age. The next year he watches an adult, 
maybe his father, sailing a crude three-masted sailing ship -
possibly his improved design- in a pond (Figure 1, middle 
pane1. When he was 12 he visited London. To him it was not 
a city of roads and shops and carriages but a great waterway 
alive with sailing activity (Figure 1, right pane1. In 1901 his 
sister, Mrs Earwicker, set out her memory of his early life. His 
first word was 'muvver'. No school would take him because 
he seemed to be unable to learn. He spent his time at home 
making ships from firewood, cotton and pins. In 1848, aged 
13, he was admitted to Essex Hall in Colchester, an institu-
tion catering for learning disability.' 
Essex Hall which later became the Royal Eastern Counties 
Asylum, was a charity set up by Rev Andrew Reed. It was 
here that his artistic talent was uncovered. In his pictorial 
autobiography he shows himself in 1848 drawing at a school 
table. There is no other young person in the picture, suggest-
ing that he was being taught on his own outside school hours 
(Figure 2, left pane1. The time on the clock is 1.45, school 
finished at 1.00. On this assumption the benign female pres-
ence is likely to be that of Mrs Sarah Pearce, identified in the 
Census of 1851 as the 38-year-old schoolmistress. Was it 
she who opened up new artistic horizons for him? The follow-
ing year, by which time he had learned to write his surname, 
he went on the Essex Hall outing to Walton-on-the-Naze. He 
portrayed a man leading the way towards the harbour. The 
masts of a ship stand out over the promenade wall. Mrs 
Pearce's husband Henry, a porter aged 40, may have been 
his guide. 
In 1850 James was moved to the Earlswood Asylum for 
Idiots, another institution set up by Andrew Reed. The Essex 
Hall educational programme had been very progressive,' and 
the young man portrays himself looking sadly back at Essex 
Hall and at his collection of 1 2 pictures, three of them depict-
ing boats (Figure 2, middle pane1. The configuration of the 
window does not match the shape of the windows in a 
contemporary sketch of Essex hall, suggesting that his work 
had been put on display in another location. 
He was put into the school at Earlswood, but his self-
portrait of 1851 is of a boy with his head buried in the tearful 
despair of failure (Figure 2, right pane1. By 1852, however, 
he was apprenticed to woodwork and boatmaking, and at his 
second attempt he produced a three-masted ship which he 
thought good enough to present to his teacher as a mark of 
appreciation (Figure 3, left pane1. His apprenticeship to 
woodworking led to the progressive complexity of his model-
ling especially after 1859. John Langdon Down, the newly 
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Sibling	  Defense	  Theory	  
•  Defense	  or	  modiﬁer	  Genes?	  –	  muta8ons	  that	  
somehow	  protect	  against	  or	  modify	  the	  eﬀects	  
of	  a	  primary	  muta8on.	  
•  Or,	  can	  female	  gender	  also	  somehow	  be	  
protec8ve	  with	  certain	  muta8ons?	  
•  Henry	  Pullen	  was	  one	  of	  13	  children,	  but	  only	  
3	  lived	  to	  adult	  life.	  His	  brother,	  William,	  was	  
also	  ins8tu8onalized	  and	  had	  excep8onal	  
ar8s8c	  skills.	  Their	  parents	  were	  ﬁrst	  cousins.	  
=ASD	  
=Odd,	  poten8al	  
broader	  
phenotype	  
=ADHD	  =ASD	  
=Odd,	  poten8al	  
broader	  
phenotype	  
New	  Syndrome	  with	  Mental	  
Retarda8on,	  “Au8sm”,	  “ADHD”	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  gene8c	  tests	  nega8ve,	  including	  
nega8ve	  for	  Fragile	  X	  and	  MANY	  candidate	  
genes.	  
•  Found	  one	  missense	  muta8on	  in	  a	  known	  
mental	  retarda8on	  gene,	  but	  the	  muta8on	  is	  a	  
very	  conserva8ve	  nonsynonymous	  Asp	  to	  Glu.	  
Is	  it	  relevant	  or	  not?	  What	  about	  the	  whole	  
rest	  of	  the	  genome?	  
Sequenced	  whole	  genomes	  of	  Mother,	  Father	  
and	  Two	  Boys,	  using	  Complete	  Genomics	  
•  Sequenced	  “whole”	  genomes	  to	  obtain	  noncoding	  and	  
other	  non-­‐exonic	  regions.	  
•  No	  obvious	  pathogenic	  CNVs	  –	  microarrays	  normal.	  
•  ~6	  million	  variants	  total	  in	  the	  4	  people	  diﬀerent	  from	  
Hg19	  reference	  genome.	  
•  No	  homozygous	  autosomal	  recessive	  muta8ons	  found.	  
•  No	  Nonsense/Frameshiz	  muta8ons	  in	  both	  boys.	  
•  2	  muta8ons	  present	  in	  mother	  and	  two	  boys,	  on	  X-­‐
chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  not	  in	  
1000Genomes	  April	  2012	  release,	  and	  not	  in	  NHLBI	  
6500	  Exomes	  
	  
2	  muta8ons	  present	  in	  mother	  and	  two	  boys,	  on	  
X-­‐chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  
not	  in	  1000Genomes	  April	  2012	  release,	  and	  not	  
in	  NHLBI	  6500	  Exomes	  
	  
•  Nonsyn	  SNV	  	  	  ZNF41	  	  	  	  c.1191C>A	  	  p.Asp397Glu	  	  
	  	  
•  Nonsyn	  SNV	  	  	  TAF1	  	  	  	  	  	  	  c.4010T>C	  	  p.Ile1337Thr	  	  
	  
TAF1	  RNA	  polymerase	  II,	  TATA	  box	  binding	  protein	  
(TBP)-­‐associated	  factor,	  250kDa	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Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Menzel,1 Udo Trautmann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
Claude Moraine,6 Jean-Pierre Fryns,7 Jamel Chelly,8 Hans-Dieter Rott,2 Hans-Hilger Ropers,1
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3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
•  KRAB	  (Kruppel-­‐associated	  box)	  domain	  -­‐A	  box.	  
•  The	  KRAB	  domain	  is	  a	  transcrip8on	  repression	  module,	  found	  
in	  a	  subgroup	  of	  the	  zinc	  ﬁnger	  proteins	  (ZFPs)	  of	  the	  C2H2	  
family,	  KRAB-­‐ZFPs.	  KRAB-­‐ZFPs	  comprise	  the	  largest	  group	  of	  
transcrip8onal	  regulators	  in	  mammals,	  and	  are	  only	  found	  in	  
tetrapods.	  	  
•  The	  KRAB	  domain	  is	  a	  protein-­‐protein	  interac8on	  module	  
which	  represses	  transcrip8on	  through	  recrui8ng	  corepressors.	  
The	  KAP1/	  KRAB-­‐AFP	  complex	  in	  turn	  recruits	  the	  
heterochroma8n	  protein	  1	  (HP1)	  family,	  and	  other	  chroma8n	  
modula8ng	  proteins,	  leading	  to	  transcrip8onal	  repression	  
through	  heterochroma8n	  forma8on.	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Figure 4 A, Pedigree of family P13, with sequence corresponding to the prolinerleucinemutation (left to right): unrelated control individual,
mother (II:1), index patient (III:2), and brother of the index patient (III:1). For the potentially affected female cousin (individual III-4) (indicated
with an asterisk [*]), no clinical data are available. Affected nucleotides are indicated with black arrows. B, Pedigree for family P42, with
sequence chromatograms indicating the splice-site mutation in affected individuals (left to right): father (I:1), mother (I:2), index patient (II:1),
and mildly affected sister (II:2). Uppercase letters indicate coding sequence; affected nucleotides are indicated with black arrows.
a diagnosis of mild MR. He was born at term (by Ce-
sarean section), with a birth weight of 3,000 g (10th–25th
percentile) and a length of 51 cm (50th percentile). He
walked at age 12–13 mo and reached early milestones
within the normal time frame; however, he exhibited a
severe language delay. He first made two-word associa-
tions at age 3 years and was first speaking in simple
phrases at age 4 years 6 mo. At age 8 years, he was 135
cm tall (90th percentile) and had a head circumference
of 53 cm (75th percentile). He had no additional dys-
morphic or neurological symptoms, and results of
screening for fragile X were negative. At age 10 years 3
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Figure 6 Northern blot hybridization of ZNF41, by use of a probe corresponding to nucleotides 621–1099 of ZNF41 transcript variant
1. A, Adult tissues (left to right): heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. B, Fetal tissues (left to right): brain,
lung, liver, and kidney.C,Adult brain structures (left to right): amygdala, caudate nucleus, corpus callosum, hippocampus, whole brain, substantia
nigra, and thalamus. Black arrowheads highlight the presence of a novel 6-kb transcript. Actin (A and C) or GAPDH (B) served as controls
for RNA loading.
sible for sequence-specific DNA binding. ZNF41, absent
in our patient, is a member of the subfamily of Krueppel-
type zinc-finger proteins harboring a highly conservedN-
terminal domain known as the Krueppel-associated box
(KRAB). Although the specific functions of ZNF41 are
not fully understood, various related genes play an es-
tablished and important role in human development and
disease (Ladomery and Dellaire 2002). In another female
patient with severe MRX and a balanced translocation,
the disorder probably resulted from the disruption of a
related X-chromosomal zinc-finger gene (Lossi et al.
2002). The X-chromosome breakpoint was located just
upstream of the Krueppel-like factor 8 (KLF8 [MIM
300286]), also known as the “ZNF741 gene,” and it was
confirmed that KLF8 transcripts were absent in the pa-
tient cell line. The Wilms tumor suppressor gene WT1
(MIM 194070), which harbors four Krueppel-type zinc
fingers, has been implicated in several urogenital devel-
opmental disorders, including WAGR syndrome (MIM
194072), which is associated with MR (Call et al. 1990;
Rose et al. 1990; Gessler et al. 1992). Of particular rel-
evance, however, are the biochemical studies that high-
light the links between the highly conserved KRAB/ZFP
subfamily of zinc-finger proteins and chromatin remod-
eling. Many disorders, several of which are associated
with MR, have been linked to defects in processes that
govern chromatin structural modification (Hendrich and
Bickmore 2001), suggesting that chromatin structural
regulationmay play a specific and important role in path-
ways critical for mental function.
Repression of transcription by a KRAB/ZFP requires
binding of the corepressor KAP-1 (also known as
“TIF1b” and “KRIP-1” [MIM 601742]) (Friedman et
al. 1996; Kim et al. 1996; Moosmann et al. 1996; Peng
et al. 2000a, 2000b). KAP-1 is a molecular scaffold that
coordinates gene-specific silencing by recruiting both
heterochromatin-associated proteins (Ryan et al. 1999)
and by interacting with the novel histone H3 Lys9–
specific methyltransferase SETDB1 (MIM 604396)
(Schultz et al. 2002). It is interesting that, within the
primary sequence of SETDB1, Schultz et al. (2002) iden-
tified a methyl CpG–binding domain that is related to
the domain found in the methyl CpG binding protein
MeCP2, which is mutated both in patients with Rett
syndrome (MIM 312750) (Amir et al. 1999) and in
patients with MRX (Couvert et al. 2001; Yntema et al.
2002). Like ZNF41, MECP2 is ubiquitously expressed;
yet loss of functional protein results in a neurological
phenotype. Although the mechanism by whichMECP2
mutations cause MR is not clear, it is well established
that MeCP2 binds to methylated CpGs and represses
transcription (for review, see Ballestar and Wolffe
[2001]), and it has recently been shown that MeCP2
associates with an unidentified methyltransferase that
specifically methylates Lys9 of histone H3 (Fuks et al.
2003), as does the KAP-1/KRAB/ZFP binding partner
SETDB1.
Further characterization of the KRAB/KAP-1 repres-
sor module has indicated that, in addition to the KRAB
domain, a bipartite domain of the plant homeodomain
(PHD) finger and a bromodomain, located within the C-
terminal portion of KAP-1, are also required for effective
gene silencing (Schultz et al. 2002). It is interesting that
the point mutations in that study were modeled after
naturally occurring mutations in the PHD finger of the
human ATRX gene, which has been implicated in both
X-linked a-thalassemia/MR syndrome (MIM 301040)
(Gibbons et al. 1995) and Juberg-Marsidi syndrome
(MIM 309590), which is also associated with MR (Vil-
lard et al. 1996a). In light of the fact that the PHD
Proving	  Causality	  
•  Will	  need	  to	  ﬁnd	  a	  second,	  unrelated	  family	  with	  same	  exact	  mu a8on	  and	  
similar	  phenotype.	  
•  Can	  also	  p rform	  in	  vitro/in	  vivo	  studies	  an 	  struct ral	  mod ling,	  and	  make	  
knock-­‐in	  mice	  and/or	  test	  in	  zebraﬁsh,	  etc…	  for	  biological	  func8on.	  
Learning	  Objec0ve	  #3:	  	  
The	  current	  state	  of	  Psychiatric	  
Gene0cs	  
-­‐  Very	  lirle	  found	  with	  GWAS	  
	  
-­‐  Some	  CNVs	  found	  by	  associa8on	  tes8ng,	  but	  proving	  
causality	  is	  an	  ongoing	  issue.	  
Some	  Deﬁni8ons	  …	  
•  The	  words	  “penetrance”	  and	  “expressivity”,	  deﬁned	  
classically	  as:	  
•  Penetrance:	  whether	  someone	  has	  ANY	  symptoms	  of	  a	  
disease,	  i.e.	  all	  or	  none,	  0%	  or	  100%.	  Nothing	  in	  between.	  
•  Expressivity:	  how	  much	  disease	  (or	  how	  many	  symptoms)	  
someone	  with	  100%	  penetrance	  has.	  
•  This	  has	  led	  to	  endless	  confusion!	  	  
•  Some	  just	  use	  the	  word	  “penetrance”	  to	  mean	  the	  
expressivity	  of	  disease,	  i.e.	  incomplete	  penetrance,	  and	  
maybe	  we	  should	  combine	  the	  two	  terms	  into	  ONE	  word	  
with	  the	  full	  expression	  from	  0-­‐100%	  of	  phenotypic	  
spectrum.	  
Deﬁni0ons.	  It	  is	  unknown	  what	  
por8on	  of	  au8sm	  will	  be	  oligogenic	  vs.	  
polygenic	  
•  Oligogenic	  –	  mul8ple	  muta8ons	  together	  
contribu8ng	  to	  aggregate	  disease,	  BUT	  with	  only	  
1	  muta8on	  of	  ~	  >10%	  penetrance	  (or	  “eﬀect	  size)	  
in	  EACH	  person.	  
•  Polygenic	  –	  Dozens	  to	  hundreds	  of	  muta8ons	  in	  
diﬀerent	  genes	  in	  the	  SAME	  person,	  together	  
contribu8ng	  to	  the	  disease	  in	  the	  SAME	  person,	  
hence	  addi0ve	  and/or	  epista0c	  contribu8on	  with	  
~0.01-­‐1%	  penetrance	  for	  each	  muta8on.	  
Example	  of	  Polygenic	  Model	  
Visscher	  et	  al.	  2011	  
Inheritance	  Pakern	  of	  Copy-­‐Number	  Variants	  and	  Frequency	  of	  Second-­‐Site	  Variants	  Associated	  with	  a	  Genomic	  
Disorder.	  
Girirajan S et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1200395 
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Understanding the spectrum of allelic variation in human genes and 
revealing the demographic and evolutionary forces that shape this varia-
tion within and among populations is a major aim of human genetics 
research. Such information is critical for defining the architecture of 
common diseases, identifying functionally important variation, and ulti-
mately facilitating the interpretation of personalized disease risk profiles 
(1–3). To date, surveys of human variation have been dominated by 
studies of single nucleotide polymorphisms (SNPs) genotyped using 
high-density arrays composed of common variants (4–6). While these 
projects have substantially improved our knowledge of common allelic 
variation and enabled genome-wide association studies (GWAS), they 
have been generally uninformative about the population genetics charac-
teristics of rare variants, defined here as a minor allele frequency (MAF) 
of less than 0.5%. 
Rare genetic variants are predicted to vastly outnumber common 
variants in the human genome (7, 8). By capturing and sequencing all 
protein-coding exons (i.e., the exome, which comprises ~1-2% of the 
human genome), exome sequencing is a powerful approach for discover-
ing rare variation and has facilitated 
the genetic dissection of unsolved 
Mendelian disorders and studying 
human evolutionary history (9–14). 
Rare and low frequency (MAF be-
tween 0.5%-1%) variants have been 
hypothesized to explain a substantial 
fraction of the heritability of common, 
complex diseases (15). Since common 
variants explain only a modest fraction 
of the heritability of most traits (16, 
17), NHLBI recently sponsored the 
multicenter Exome Sequencing Project 
(ESP), to identify novel genes and 
molecular mechanisms underlying 
complex heart, lung, and blood disor-
ders by sequencing the exomes of a 
large number of individuals measured 
for phenotypic traits of substantial 
public health significance (e.g., early-
onset myocardial infarction, stroke, 
body mass index). 
Data generation and variant dis-
covery. A total of 63.4 terabases of 
DNA sequence was generated at two 
centers with three complimentary defi-
nitions of the exome target and two 
different capture technologies (18). We 
sequenced samples from 14 different 
cohorts in the ESP to an average medi-
an depth of 111x (range 23x – 474x). 
We found no evidence of cohort- 
and/or phenotype specific effects, or 
other systematic biases, in the analysis 
of the filtered SNV data (18; Figs. S1-
S7). Exomes from related individuals 
were excluded from further analysis 
(18; Fig. S8) resulting in a dataset of 
2,440 exomes. We inferred genetic 
ancestry using a clustering approach 
(18), and focused the remaining anal-
yses on the inferred 1,351 EA and 
1,088 AA individuals. We subjected 
the 563,698 variants in the intersection 
of all three capture targets to standard 
quality control filters (18) resulting in a final data set of 503,481 single 
nucleotide variants (SNVs) identified in 15,585 genes and 22.38 Mb of 
targeted sequence per individual. We assessed data quality and error 
rates using complementary strategies (18). Approximately 98% 
(941/961) of all variant sites that were experimentally tested were con-
firmed, including 98% (234/238) of singletons, 98% (678/693) of non-
singleton SNV sites with a MAF < 10%, and 97% (29/30) of SNV sites 
ZLWKD0$) 
The vast majority of coding variation is rare and novel. We ob-
served a total of 503,481 SNVs and 117 fixed, non-reference sites, of 
which 325,843 and 268,903 were found in AA and EA, respectively (18; 
Fig. S9A). Excluding singletons, ~58% of SNVs were population-
specific (93,278 and 32,552 variants were uniquely observed in AA, or 
EA, respectively), and the vast majority of these variants were rare (18; 
Fig. S9B). Most SNVs (292,125 or 58%) were nonsynonymous includ-
ing 285,960 missense variants and 6,165 nonsense variants (18; Fig. 
S9C). Synonymous variants accounted for 38% (188,975) of the total 
SNVs (18; Fig. S9C), with the remaining 4% of SNVs (22,381) located 
Evolution and Functional Impact of 
Rare Coding Variation from Deep 
Sequencing of Human Exomes 
Jacob A. Tennessen,1* Abigail W. Bigham,2*† Timothy D. O’Connor,1* Wenqing 
Fu,1 Eimear E. Kenny,3 Simon Gravel,3 Sean McGee,1 Ron Do,4,5 Xiaoming Liu,6 
Goo Jun,7 Hyun Min Kang,7 Daniel Jordan,8 Suzanne M. Leal,9 Stacey Gabriel,4 
Mark J. Rieder,1 Goncalo Abecasis,7 David Altshuler,4 Deborah A. Nickerson,1 
Eric Boerwinkle,6,10 Shamil Sunyaev,4,8 Carlos D. Bustamante,3 Michael J. 
Bamshad,1,2‡ Joshua M. Akey,1‡ Broad GO, Seattle GO, on behalf of the NHLBI 
Exome Sequencing Project 
1Department of Genome Sciences, University of Washington, Seattle, Washington, USA. 2Department of 
Pediatrics, University of Washington, Seattle, Washington, USA. 3Department of Genetics, Stanford 
University, Stanford, California, USA. 4Broad Institute of MIT and Harvard, Cambridge, Massachusetts, 
USA. 5The Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, 
USA. 6Human Genetics Center, University of Texas Health Sciences Center at Houston, Houston, Texas, 
USA. 7Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA. 8Division of Genetics, 
Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. 9Department of Molecular and 
Human Genetics, Baylor College of Medicine, Houston, TX, USA. 10Human Genome Sequencing Center, 
Baylor College of Medicine, Houston, Texas, USA. 
*These authors contributed equally to this work. 
†Present address: Department of Anthropology, University of Michigan, Ann Arbor, MI, USA. 
‡To whom correspondence should be addressed. E-mail: akeyj@uw.edu (J.M.A.); 
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As a first step toward understanding how rare variants contribute to risk for 
complex diseases, we sequenced 15,585 human protein-coding genes to an average 
median depth of 111x in 2,440 individuals of European (n=1,351) and African 
(n=1,088) ancestry. We identified >500,000 single nucleotide variants (SNVs), the 
majority of which were rare (86% with a minor allele frequency < 0.5%), novel (82%), 
and population-specific (82%). On average, 2.3% of the 13,595 SNVs each person 
carries were predicted to impact protein function of ~313 genes per genome, and 
~95.7% of SNVs predicted to be functionally important were rare. This excess of rare 
functional variants is due to the combined effects of explosive, recent accelerated 
population growth and weak purifying selection. Furthermore, we show that large 
sample sizes will be required to associate rare variants with complex traits. 
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Crohn’s disease and ulcerative colitis are classified as chronic, idi-
opathic inflammatory bowel diseases (IBDs) of the gastrointestinal 
tract with unknown etiology (MIM266600). Crohn’s disease occurs 
in about 100–150 per 100,000 individuals of European a cestry1. 
Generally, the disease affects the ileum and colon, but it can affect any 
region of the gut. Ulcerative colitis has similar population prevalence, 
and although it has some similarities to Crohn’s disease in clinical 
manifestation, the location of inflammation is limited to the colonic 
mucosa. Strong familial aggregation has been observed in twin studies 
of Crohn’s disease and ulcerative colitis2,3. Recent population-based 
sibling risk is 26-fold greater for Crohn’s diseas  and 9-fold greater for 
ulcerative colitis2, and overall Crohn’s disease and ulcerative colitis 
concordance rates in nonselected twin studies are 30% and 15%, 
respectively, among monozygotic twins compared with 4% for 
Crohn’s disease or ulcerative colitis among dizygotic twins3. Like most 
complex diseases, Crohn’s disease and lcerative colitis result from 
a combination of genetic and nongenetic risk factors, and each 
individual factor probably has a modest effect on disease risk4.
Deep resequencing of GWAS loci identifies independent 
rare variants associated with inflammatory bowel disease
Manuel A Rivas1–3, Mélissa Beaudoin4,23, Agnes Gardet5,23, Christine Stevens2,23, Yashoda Sharma6,  
Clarence K Zhang6, Gabrielle Boucher4, Stephan Ripke1,2, David Ellinghaus7, Noel Burtt2, Tim Fennell2,  
Andrew Kirby1,2, Anna Latiano8, Philippe Goyette4, Todd Green2, Jonas Halfvarson9, Talin Haritunians10,  
Joshua M Korn2, Finny Kuruvilla2,11, Caroline Lagacé4, Benjamin Neale1,2, Ken Sin Lo4, Phil Schumm12,  
Leif Törkvist13, National Institute of Diabetes and Digestive Kidney Diseases Inflammatory Bowel Disease 
Genetics Consortium (NIDDK IBDGC)14, United Kingdom Inflammatory Bowel Disease Genetics Consortium14, 
International Inflammatory Bowel Disease Genetics Consortium14, Marla C Dubinsky15, Steven R Brant16,17, 
Mark S Silverberg18, Richard H Duerr19,20, David Altshuler1,2, Stacey Gabriel2, Guillaume Lettre4, Andre Franke7, 
Mauro D’Amato21, Dermot P B McGovern10,22, Judy H Cho6, John D Rioux4, Ramnik J Xavier1,2,5 & Mark J Daly1,2
More than 1,000 susceptibility loci have been identified through genome-wide association studies (GWAS) of common variants; 
however, the specific genes and full allelic spectrum of causal variants underlying these findings have not yet been defined. Here 
we used pooled next-generation sequencing to study 56 genes from regions associated with Crohn’s disease in 350 cases and 350 
controls. Through follow-up genotyping of 70 rare and low-frequency protein-altering variants in nine independent case-control 
series (16,054 Crohn’s disease cases, 12,153 ulcerative colitis cases and 17,575 healthy controls), we identified four additional 
independent risk factors in NOD2, two additional protective variants in IL23R, a highly significant associa i n with a protective 
splice varia t in CARD9 (P < 1 × 10−16, odds ratio y 0.29) and additional associations with coding variants in IL18RAP, CUL2, 
C1orf106, PTPN22 and MUC19. We extend the results of successful GWAS by identifying new, rare and probably functional 
variants that could aid functional experiments and predictive models.
1Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. 2Broad Institute of Harvard and MIT, Cambridge, 
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Sweden. 14A full list of consortium members is provided in the Supplementary Note. 15The Pediatric Inflammatory Bowel Disease Center, Cedars-Sinai Medical  
Center, Los Angeles, California, U A. 16Meyerhoff Inflammatory B w l Disease Center, Department of Medicine, School of Medicine, Johns Hopkins University, 
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Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. 23These authors contributed equally to this work. 
Correspondence should be addressed to M.J.D. (mjdaly@atgu.mgh.harvard.edu) or M.A.R. (rivas@broadinstitute.org).
Received 5 January; accepted 31 August; published online 9 October 2011; doi:10.1038/ng.952
Neuron
Article
High Frequencies of De Novo CNVs
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SUMMARY
While it is known that rare copy-number variants
(CNVs) contribute to risk for some neuropsyc iatric
disorders, the role of CNVs in bipolar disorder is
unclear. Here, we reasoned that a contribution of
CNVs to mood disorders might be most evident for
de novo mutations. We performed a genome-wide
an lysis of de novo CNVs in a cohort of 788 rios.
Diagnoses of offspring included bipolar disorder
(n = 185), schizophre ia ( = 177), and healthy
controls (n = 426). Frequencies of de novo CNVs
were significantly higher in bipolar disorder as com-
pared with controls (OR = 4.8 [1.4,16.0], p = 0.009).
De novo CNVs were particularly enriched among
cases with an age at onset younger than 18 (OR =
6.3 [1.7,22.6], p = 0.006). We also confirmed a signifi-
cant enrichment of de novo CNVs in schizophrenia
(OR = 5.0 [1.5,16.8], p = 0.007). Our results suggest
that rare spontaneous mutations are an important
contributor to risk for bipolar diso der and other
major neurop ychiatric diseases.
INTRODUCTION
Bipolar disorder (BD, also known s a ic-depressive illness) is
a severe ood disord r onsisti g of episodes of mania and
epression. The lifetime prevalence of bipolar disorder in the
gen ral population is !1% and the illness i associated with
consid rable morbidity and a high lif time isk of suicide (Meri-
kangas et al., 2011).
Genes play an important r le in risk for BD. Th rate of concor-
dance formonozygotic twins is 40%, comparedwith a 5% rate in
dizygotic twins (Kendler et al., 1995; Kieseppa¨ et al., 2004;
McGuffin et al., 2003), and risk among the first-degree relatives
of individuals with BD is ten-fold greater than risk among the
general population (Barnett and Smoller, 2009). However, as
with other psychiatric disorders, the genetics of BD is complex,
Neuron 72, 951–963, December 22, 2011 ª2011 Elsevier Inc. 951
Rare	  Variants	  –	  CNVs,	  SNVs,	  indels,	  etc…	  in	  Rare	  AND	  Common	  diseases	  
Phenotypic	  Varia0on	  Associated	  with	  Addi0onal	  Large	  Copy-­‐Number	  Variants.	  
Girirajan S et al. N Engl J Med 2012. DOI: 10.1056/
NEJMoa1200395 
CNVs in Schizophrenia 
•  del	  22q11	  &	  schizophrenia	  (Murphy	  1999)	  	  
•  GLUR7	  (gain),	  CACNG2	  (loss)	  and	  AKAP5	  (gain)	  in	  brain	  8ssue	  (n=35)	  
(Wilson	  2006)	  
•  del	  15q13.3	  and	  1q21.1	  (n=3391)	  (Stone	  2008)	  
–  Also	  found	  1.15x	  more	  CNVs<100kb	  
•  Novel	  CNVs	  found	  (n=150)	  (Walsh	  2008)	  
–  5%	  of	  controls	  vs	  15%	  of	  cases	  vs	  20%	  of	  early-­‐onset	  scz	  
•  CNVs	  >1	  Mb	  were	  2.26x	  more	  common	  in	  cases	  (Kirov	  2009)	  
•  In	  the	  last	  couple	  of	  years:	  
–  1q21,	  15q11.2,	  15q13.3,	  16p11.2,	  22q12,	  Neurexin	  1,	  etc….	  
CNVs in Bipolar 
•  dup	  GSK3beta	  (Wnt	  signaling,	  Li	  target)	  (Lachman	  2007)	  
•  CNVs>100kb	  in	  16.2%	  of	  cases	  vs	  12.3%	  of	  controls	  (Zhang	  2009)	  
•  More	  pending….	  
CNVs	  &	  Au0sm	  Suscep0bility	  
(Cook	  &	  Scherer,	  Nature	  2008)	  
& Autism 
•  Dele8on	  or	  duplica8on	  at	  16p11.2	  in	  ~1%	  of	  ASD	  (Weiss	  2008)	  
–  Del	  in	  5/512	  (Boston),	  3/299	  (Iceland)	  vs.	  2/18,834	  controls	  (Iceland)	  
–  Dup	  in	  7/751	  (AGRE),	  4/512	  (Boston)	  
•  Neurexin	  1	  (Kim	  2008)	  
•  Contac8n	  4	  (Fernandez	  2008)	  
•  Ubiqui8n	  pathway	  genes	  (UBE3A,	  PARK2,	  RFWD2,	  FBXO40)	  (Glessner	  
2009)	  
–  Also	  found	  neuronal	  cell	  adhesion	  genes	  (NLGN1	  &	  ASTN2)	  
•  SHANK3	  dele8ons	  in	  up	  to	  1%	  of	  ASD	  
–  Associated	  with	  lower	  func8oning	  au8sm?	  (Sykes	  2009)	  
–  Located	  at	  22q13.3	  &	  encodes	  a	  scaﬀold	  protein	  
•  Others:	  DOCK4,	  AUTS1,	  AUTS5	  
•  15q13.3	  microdele8on	  
•  Maternally	  inherited	  15q11-­‐13	  in	  3-­‐5%	   	  	  
–  Paternal	  inheritance	  of	  dup15q11-­‐13	  less	  severe	  

“A	   primary	   jus8ﬁca8on	   for	   any	   gene8c	   study	   of	   a	   condi8on	   of	  
uncertain	   e8ology	  must	   surely	   be	   to	   shed	   light	   on	   the	   biological	  
causes….	   Focused	   studies	   on	   individual	   cases,	   single	   families	   or	  
gene8cally	  homogeneous	  popula8ons	  do	  not	  currently	  arract	  the	  
same	   cash	   or	   cachet	   as	   consor8um-­‐based	   GWAS	   studies,	   but	  
promise	   greater	   returns	   in	   terms	   of	   biological	   insight	   and	  
e8ological	  understanding.”	  
	  
	  
Mitchell	  and	  Porteous	  

Trends	  Mol	  Med.	  2011	  Oct	  18.	  	  
DISC1	  at	  10:	  connec0ng	  psychiatric	  	  
gene0cs	  and	  neuroscience.	  
Porteous	  DJ,	  Millar	  JK,	  Brandon	  NJ,	  Sawa	  A.	  
	  
1	  
1q42 
11q14 
11	  
The	  t(1;11)	  breakpoint	  &	  linkage	  to	  psychosis	  
 t(1;11) 
 YES 
N=36 
NO 
N=35 
Schizophrenia 7 0 
Bipolar affective disorder 1 0 
Recurrent major depression 10 0 
   
Conduct disorder with anxiety in 
adolescence 
2 1 
Minor depression 1 3 
Alcoholism 0 1 
 
 
LOD	  =	  3.4	  
MLOD	  =	  7.1	  
Dominant,	  variable	  penetrance,	  broad	  diagnosis	  	  
Slide	  courtesy	  of	  David	  Porteous	  
	  
	  
?	  
	  
71940	  
YGTSS=0	  
YBOCS=21	  
	  
	  
	  
	  
	  
71938	  
YGTSS=35	  
YBOCS=YES	  
	  
	  
	  
	  
	  
	  
	  
71939	  
YGTSS=NO	  
YBOCS=8	  
	  
?	  
	  
71941	  
YGTSS=?	  
YBOCS=?	  
	  
	  
	  
	  
	  
	  
	  
	  
71944	  
YGTSS=YES,	  A1	  
YBOCS=28	  
	  
	  
?	  
	  
71943	  
YGTSS=?	  
YBOCS=15	  
	  
	  
	  
	  
71945	  
YGTSS=21	  
YBOCS=7	  
	  
	  
	  
	  
73881	  
YGTSS=YES,	  A2	  
YBOCS=7	  
	  	  
	  
	  
	  
	  
?	  
	  
69849	  
YGTSS=0	  
YBOCS=20	  
	  
	  
?	  
	  
71775	  
YGTSS=?	  
YBOCS=6	  
	  
	  
	  
	  
69850	  
YGTSS=17	  
YBOCS=24	  
	  
	  
	  
	  
	  
	  
?	  
	  
71777	  
YGTSS=7	  
YBOCS=19	  
	  
	  
	  
	  
71776	  
YGTSS=55	  
YBOCS=29	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
73880	  
YGTSS=YES,	  A1	  
YBOCS=YES	  
	  
	  
	  
	  
	  
	  
	  
?	  
	  
71942	  
YGTSS=?	  
YBOCS=?	  
	  
	  
	  
	  
	  
	  
	  
	  
71946	  
YGTSS=17,	  A2	  
YBOCS=subclinical	  
	  
	  
?	  
	  
70851	  
YGTSS=NO	  
YBOCS=21	  
	  
	  
	  
	  
	  
	  
	  
	  
70852	  
YGTSS=Yes,	  B1	  
YBOCS=17	  
	  
	  
	  
?	  
	  
?	  
	  
	  
?	  
	  
?	  
	  
	  
	  
	  
	  
	  
	  
73879	  
YGTSS=0	  
YBOCS=0	  
	  
Branch	  1	  
Phenotyping	  
Tic	  Disorders	   OCD	  
ADHD	  
5	  
21	  
14	  
19	  
2	  
1	   0	  
12	  UNAFFECTED	  with	  
8cs,	  OCD	  or	  ADHD	  
Large	  Pedigree	  with	  74	  collected	  and	  phenotyped	  members	  
Waddington	  claimed	  that	  canals	  form	  in	  the	  epigene0c	  
landscape	  during	  evolu0on,	  and	  that	  this	  heuris0c	  is	  useful	  for	  
understanding	  the	  unique	  quali0es	  of	  biological	  robustness.	  
The	  canalisa8on	  metaphor	  suggests	  that	  phenotypes	  are	  very	  robust	  to	  small	  perturba8ons,	  
for	  which	  development	  does	  not	  exit	  the	  canal,	  and	  rapidly	  returns	  back	  down,	  with	  lirle	  
eﬀect	  on	  the	  ﬁnal	  outcome	  of	  development.	  But	  perturba8ons	  whose	  magnitude	  exceeds	  a	  
certain	  threshold	  will	  break	  out	  of	  the	  canal,	  moving	  the	  developmental	  process	  into	  
uncharted	  territory.	  Strong	  robustness	  up	  to	  a	  limit,	  with	  lirle	  robustness	  beyond,	  is	  a	  parern	  
that	  could	  increase	  evolvability	  in	  a	  ﬂuctua8ng	  environment.	  
“Biological	  Indeterminacy”	  
•  Bateson	  became	  famous	  as	  the	  outspoken	  
Mendelian	  antagonist	  of	  Walter	  Raphael	  Weldon,	  
his	  former	  teacher,	  and	  Karl	  Pearson	  who	  led	  the	  
biometric	  school	  of	  thinking.	  This	  concerned	  the	  
debate	  over	  salta8onism	  versus	  gradualism	  
(Darwin	  had	  been	  a	  gradualist,	  but	  Bateson	  was	  a	  
salta8onist).	  Later,	  Ronald	  Fisher	  and	  
J.B.S.	  Haldane	  showed	  that	  discrete	  muta8ons	  
were	  compa8ble	  with	  gradual	  evolu8on:	  see	  the	  
modern	  evolu8onary	  synthesis.	  
Biological	  Indeterminacy.	  Greenspan	  RJ.	  Sci	  Eng	  
Ethics.	  2012	  Jul	  3	  
	  
Beyond	  our	  Kuhnian	  inheritance	  
A	  recent	  lecture	  by	  Prof	  Greg	  Radick	  ques8ons	  our	  scien8ﬁc	  inheritance,	  
through	  textbook	  histories	  of	  gene8cs	  and	  Thomas	  Kuhn's	  legacy	  
hrp://www.guardian.co.uk/science/the-­‐h-­‐word/2012/aug/28/thomas-­‐
kuhn	  
Walter	  Frank	  Raphael	  Weldon	  
Vs.	  	  
William	  Bateson	  
Forthcoming	  by	  Greg	  Radick.	  Scholarly	  edi8on	  of	  W.	  F.	  R.	  Weldon's	  Theory	  of	  
Inheritance	  (1904-­‐1905),	  coedited	  with	  Annie	  Jamieson.	  
E.	  coli	  adap8ng	  to	  low	  glucose	  condi8ons,	  in	  the	  context	  of	  media	  containing	  citrate.	  
"Finally,	  novel	  func8ons	  ozen	  emerge	  in	  rudimentary	  forms	  that	  must	  be	  reﬁned	  to	  
exploit	  the	  ecological	  opportuni8es.	  This	  three-­‐step	  process	  —	  in	  which	  poten8a8on	  
makes	  a	  trait	  possible,	  actualiza8on	  makes	  the	  trait	  manifest,	  and	  reﬁnement	  makes	  
it	  eﬀec8ve	  —	  is	  probably	  typical	  of	  many	  new	  func8ons.”	  -­‐	  Lemski	  
Genomic	  analysis	  of	  a	  key	  innova8on	  in	  an	  experimental	  Escherichia	  coli	  popula8on.	  
Blount	  ZD,	  Barrick	  JE,	  Davidson	  CJ,	  Lenski	  RE.	  
Nature.	  2012	  Sep	  19.	  doi:	  10.1038/nature11514	  
	  
Genotype	  First,	  Phenotype	  Second	  
AND	  Longitudinally	  
Phenotypic variability and genetic susceptibility
to genomic disorders
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The duplication architecture of the human genome predisposes our species to recurrent copy number
variation and disease. Emerging data suggest that this mechanism of mutation contributes to both
common and rare diseases. Two features regarding this form of mutation have emerged. First, common
structural polymorphisms create susceptible and protective chromosomal architectures. These structural
polymorphisms occur at varying frequencies in populations, leading to different susceptibility and ethnic
predilection. Second, a subset of rearrangements shows extreme variability in expressivity. We propose
that two types of genomic disorders may be distinguished: syndromic forms where the phenotypic features
are largely invariant and those where the same molecular lesion associates with a diverse set of diagnoses
including epilepsy, schizophrenia, autism, intellectual disability and congenital malformations. Copy number
variation analyses of patient genomes reveal that disease type and severity may be explained by the occur-
rence of additional rare events and their inheritance within families. We propose that the overall burden of
copy number variants creates differing sensitized backgrounds during development leading to different
thresholds and disease outcomes. We suggest that the accumulation of multiple high-penetrant alleles
of low frequency may serve as a more general model for complex genetic diseases, posing a significant
challenge for diagnostics and disease management.
INTRODUCTION
Genomic disorders were originally described as large deletions
and duplications that are highly penetrant, mostly de novo in
origin, and typically identified in affected individuals with intel-
lectual disability/multiple congenital malformations. Some
examples include Smith–Magenis syndrome (MIM: 182290),
DiGeorge/velocardiofacial syndrome (MIM: 188400, 192430)
andWilliams–Beuren syndrome (MIM: 194050). These classi-
cal genomic disorders have been well characterized in the past
two decades with genotype–phenotype correlation studies
implicating causative genes, mouse models recapitulating the
human clinical features, and standardized management proto-
cols and support groups established.
Application of higher definition molecular techniques,
including single-nucleotide polymorphism microarrays or
array comparative genomic hybridization (CGH), has allowed
genotyping of larger disease cohorts and controls. Two major
principles have emerged from these more recent studies: (i)
common copy number polymorphism predisposes certain
chromosomes to recurrent deletions and duplications and
(ii) association of the same recurrent genomic lesion with
apparently very diverse phenotypes. The latter has begun to
illuminate common neurodevelopmental pathways and
helps to explain the comorbidity of diverse neurological
manifestations within the same families. The distinction
between variability of expressivity and reduced penetrance
depending on the diagnosis has become an important consider-
ation for these rare mutational events. We will explore the
mechanisms, models and implications underlying these two
different aspects.
GENOMIC SUSCEPTIBILITY TO RECURRENT
DELETIONS AND DUPLICATIONS
Seminal work on Charcot–Marie–Tooth disease (1,2) and
hereditary neuropathy with liability to pressure palsies
(HNPP) (3) directly implicated low-copy repeats or segmental
duplications as substrates for unequal crossover or non-allelic
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Objective: The authors used a genome-
wide association study (GWAS) of multiply
affected families to investigate the associ-
ation of schizophrenia to common single-
nucleotide polymorphisms (SNPs) and rare
copy number variants (CNVs).
Method: The family sample included
2,461 individuals from 631 pedigrees (581
in the primary European-ancestry analyses).
Association was tested for single SNPs and
genetic pathways. Polygenic scores based
on family study results were used to predict
case-control status in the Schizophrenia
Psychiatric GWAS Consortium (PGC) data
set, and consistency of direction of effect
with the family study was determined for
top SNPs in the PGC GWAS analysis. Within-
family segregation was examined for
schizophrenia- ss ciated rare CNVs.
Results: No genome-wide signiﬁcant asso-
ciationswereobserved for single SNPs or for
pathways. PGC case and control subjects
had signiﬁcantly different genome-wide
polygenic scores (computed by weighting
their genotypes by log-odds ratios from the
family study) (best p=10217, explaining
0.4% of the variance). Family study and
PGC analyses had consistent directions for
37 of the 58 independent best PGC SNPs
(p=0.024). The overall frequency of CNVs
in regions with reported associations
with schizophrenia (chromosomes 1q21.1,
15q13.3, 16p11.2, and 22q11.2 and the
neurexin-1 gene [NRXN1]) was similar to
previou case-control studies. NRXN1
deletions and 16p11.2 duplications (both
of which were transmitted from parents)
and 22q11.2 deletions (de novo in four
cases) did not segregate with schizophre-
nia in families.
Conclusions: Many common SNPs are
likely to contribute to schizophrenia risk,
with substantial overlap in genetic risk
factors between multiply affected families
and ses in l rge case-control st dies. Our
ﬁndings are consistentwith a role for speciﬁc
CNVs in disease pathogenesis, but the partial
segregationof someCNVswith schizophrenia
suggests that researchers should exercise
caution in using them for predictive genetic
testing until their effects in diverse popula-
tions have been fully studied.
Am J Psychiatry Levinson et al.; AiA:1–11
We report here on the ﬁrst genome-wide associ-
ation study (GWAS) in families with multiple members
with schizophrenia. Signiﬁcant associations of single-
nucleotide polymorphisms (SNPs) can suggest new
disease susceptibility mechanisms. For schizophrenia,
large GWAS analyses of common SNPs have found
associations in the major histocompatibility complex
(MHC, chromosome 6) (1–3) and several speciﬁc genes
AJP in Advanced ajp.psychiatryonline.org 1
Article
Genome-Wide Association Study of Multiplex
Schizophrenia Pedigrees
Douglas F. Levinson, M.D.
Jianxin Shi, Ph.D.
Kai Wang, Ph.D.
Sang Oh, M.Sc.
Brien Riley, Ph.D.
Ann E. Pulver, Ph.D.
Dieter B. Wildenauer, Ph.D.
Claudine Laurent, M.D., Ph.D.
Bryan J. Mowry, M.D.,
F.R.A.N.Z.C.P.
Pablo V. Gejman, M.D.
Michael J. Owen, Ph.D.,
F.R.C.Psych.
Kenneth S. Kendler, M.D.
Gerald Nestadt, M.D.
Sibylle G. Schwab, Ph.D.
Jacques Mallet, Ph.D.
Deborah Nertney, B.Sc.
Alan R. Sanders, M.D.
Nigel M. Williams, Ph.D.
Brandon Wormley, B.S.
Virginia K. Lasseter, B.A.
Margot Albus, M.D.
Stephanie Godard-Bauché, M.S.
Madeline Alexander, Ph.D.
Jubao Duan, Ph.D.
Michael C. O’Donovan, Ph.D.,
F.R.C.Psych.
Dermot Walsh, M.D.
Anthony O’Neill, M.D.
George N. Papadimitriou, M.D.
Dimitris Dikeos, M.D.
Wolfgang Maier, M.D.
Bernard Lerer, M.D.
Dominique Campion, M.D.,
Ph.D.
David Cohen, M.D., Ph.D.
Maurice Jay, M.D.
Ayman Fanous, M.D.
Peter Eichhammer, M.D.
Jeremy M. Silverman, Ph.D.
Nadine Norton, Ph.D.
Nancy Zhang, Ph.D.
Hakon Hakonarson, M.D., Ph.D.
Cynthia Gao, M.S.
Ami Citri, Ph.D.
Mark Hansen, Ph.D.
Stephan Ripke, M.D.
The Schizophrenia Psychiatric
GWAS Consortium
Frank Dudbridge, Ph.D.
Peter A. Holmans, Ph.D.
Objective: The authors used a genome-
wide associati n study (GWAS) of multiply
affected families to investigate the associ-
ation of schizophrenia to common single-
nucleotide polymorphisms (SNPs) and rare
copy number variants (CNVs).
Method: The family sample included
2,461 in ividuals from 631 pedigrees (581
in the primary European-ancestry analyses).
Association was tested for single SNPs and
genetic pathways. Polygenic scores based
on family study results were used to predict
case-control status in the Schizophrenia
Psychiatric GWAS Consortium (PGC) data
set, and consistency of direction of effect
with the family study was determined for
top SNPs in the PGC GWAS analysis. Within-
family segregation was examined for
schizophrenia-associated rare CNVs.
Results: No genome-wide signiﬁcant asso-
ciationswereobserved for single SNPs or for
pathways. PGC case and control subjects
had signiﬁcantly different genome-wide
polygenic scores (computed by weighting
their genotypes by log-odds ratios from the
family study) (best p=10217, explaining
0.4% of the variance). Family study and
PGC analyses had consistent directions for
37 of the 58 independent best PGC SNPs
(p=0.024). The overall frequency of CNVs
in regions with reported associations
with schizophrenia (chromosomes 1q21.1,
15q13.3, 16p11.2, and 22q11.2 and the
neurexin-1 gene [NRXN1]) was similar to
previous case-control studies. NRXN1
deletions and 16p11.2 duplications (both
of which were transmitted from parents)
and 22q11.2 deletions (de novo in four
cases) did not segregate with schizophre-
nia in families.
Conclusions: Many common SNPs are
likely to contribute to schizophrenia risk,
with substantial overlap in genetic risk
factors between multiply affected families
and cases in large case-control studies. Our
ﬁndings are consistentwith a role for speciﬁc
CNVs in disease pathogenesis, but the partial
segregationof someCNVswith schizophrenia
suggests that researchers should exercise
caution in using them for predictive genetic
testing until their effects in diverse popula-
tions have been fully studi d.
Am J Ps chiatry Levinson et al.; AiA:1–11
We report here on the ﬁrst genome-wide associ-
ation study (GWAS) in families with multipl members
with schizophrenia. Signiﬁcant associations of single-
nucleotide polymorphisms (SNPs) can suggest new
disease susceptibility mechanis s. For schizophrenia,
large GWAS analyses of common SNPs have found
associations in the major histoc mpatibility complex
(MHC, chromosome 6) (1–3) an several speciﬁc genes
AJP in Advanced ajp.psychiat y nline.org 1
“Rare	  CNVs	  wer 	   bserve 	  in	  regions	  with	   trong	  previ u ly	   cum n ed	  associa8on	  
with	  schizophrenia,	  but	  with	  variable	  parerns	  of	  segrega8on.	  This	  should	  serve	  as	  a	  
reminder	  that	  we	  s8ll	  know	  rela8vely	  lirle	  about	  the	  distribu8on	  of	  these	  CNVs	  in	  the	  
en8re	  popula8on	  (e.g.,	  in	  individuals	  with	  no	  or	  only	  mild	  cog i8ve	  problems)	  or	  about	  
the	  reas ns	   or	  the	  emerg nce	   f	  sc izophrenia	  in	  only	  a	   inority	   f	  c rriers,	  so	  great	  
cau8on	  is	  required	  in	  gene8c	  counseling	  and	  prediagnosis.”	  	  
	  
Penetrance	  Issues	  
•  We	  do	  not	  really	  know	  the	  penetrance	  of	  	  prery	  much	  
ALL	  muta8ons	  in	  humans,	  as	  we	  have	  not	  
systema8cally	  sequenced	  or	  karyotyped	  any	  gene8c	  
altera8on	  in	  Thousands	  to	  Millions	  of	  randomly	  
selected	  people,	  nor	  categorized	  into	  ethnic	  classes,	  
i.e.	  clans.	  
•  There	  is	  a	  MAJOR	  clash	  of	  world-­‐views,	  i.e.	  do	  single	  
muta8ons	  drive	  outcome	  predominately,	  or	  are	  the	  
results	  modiﬁed	  substan8ally	  by	  gene8c	  background	  
and/or	  environment?	  i.e.	  is	  there	  really	  such	  a	  thing	  as	  
gene8c	  determinism	  for	  MANY	  muta8ons?	  
Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked	  for	  thousands	  of	  
volunteer	  families.	  
Pa0entsLikeMe	  
Industrializa8on	  of	  Genome	  Sequencing	  –	  
Just	  like	  what	  happened	  in	  development	  of	  
MRI	  
•  09/11/12
Illumina	  Announces	  Expedited	  Individual	  Genome	  
Sequencing	  Service	  (IGS)	  
•  09/11/12
Illumina	  and	  Partners	  HealthCare	  Announce	  Alliance	  to	  
Introduce	  Next-­‐Genera8on	  Sequencing	  Clinical	  
Interpreta8on	  and	  Repor8ng	  Tools	  
•  09/11/12
Illumina	  Launches	  TruSightTM	  Targeted	  Sequencing	  
Content	  Sets	  

For	  now,	  more	  eﬀort	  should	  be	  placed	  
on	  the	  following:	  
•  Implemen8ng	  Standards	  for	  a	  “clinical-­‐grade”	  exome,	  
and	  promo8ng	  the	  “networking	  of	  science”	  model.	  
•  Focusing	  on	  rare,	  highly	  penetrant	  muta8ons	  running	  
in	  families,	  with	  cascade	  carrier	  tes8ng	  of	  even	  more	  
rela8ves	  as	  needed.	  
•  The	  genomic	  background	  is	  much	  more	  constant	  in	  
families.	  
•  The	  environmental	  background	  is	  some8mes	  more	  
constant	  in	  families.	  
•  This	  allows	  one	  to	  ﬁgure	  out	  penetrance	  of	  rare	  
variants	  in	  these	  families,	  along	  with	  other	  issues,	  
such	  as	  soma8c	  mosaicism.	  
Conclusions	  from	  Learning	  Objec8ves	  
1.  Par8cipants	  will	  learn	  about	  the	  current	  state	  
of	  gene8cs,	  including	  genome	  wide	  
associa8on	  studies	  (GWAS),	  Copy	  Number	  
Variants	  (CNVs)	  and	  next	  genera8on	  
sequencing.	  
2.  Some	  Case	  Illustra8ons	  will	  be	  presented.	  	  
3.  A	  review	  of	  current	  progress	  in	  psychiatric	  
	  gene8cs	  will	  be	  presented.	  
Figure 4.	

	

Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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